Roche, Alzheimer's
An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...
The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...
Roche revealed early-stage data for a new Alzheimer’s program on Wednesday as it seeks to jump back into a field littered ...
These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...
Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...
With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.
Roche Holding AG said its third-quarter sales rose thanks to eye drug Vabysmo as well as medicines for cancer, hemophilia and ...
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback